| Autor: |
Chu DK; Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe's Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont. chudk@mcmaster.ca., Oykhman P; Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe's Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont., Sussman GL; Division of Clinical Immunology and Allergy, Department of Medicine (Chu, Oykhman), and Department of Health Research Methods, Evidence & Impact (Chu), McMaster University and The Research Institute of St. Joe's Hamilton, Ont.; Division of Clinical Immunology & Allergy (Sussman), Department of Medicine, University of Toronto, Toronto, Ont. |
| Abstrakt: |
Competing Interests: Competing interests: Derek Chu is a CAAIF-CSACI-AllerGen Emerging Clinician-Scientist Research Fellow, supported by the Canadian Allergy, Asthma and Immunology Foundation, the Canadian Society of Allergy and Clinical Immunology and AllerGen NCE Inc. (the Allergy, Genes and Environment Network). Gordon Sussman reports grants and personal fees from Novartis, Aralez, CSL Behring, Sanofi, Pediapharm, GSK, Genentech, DBV technologies, Aimmune, AstraZeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Shire, Leopharma, Regeneron and mdBriefCase and grants from Novartis, GSK, Genentech, DBV technologies, Aimmune, CSL Behring, AstraZeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Leo Pharma, Regeneron, Sanofi, Blueprint, ALK, Amgen and Cliantha outside the submitted work. No other competing interests were declared. |
